Author: admin

DelveInsight’s “PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the PD-1 Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the PD-1 Non-Small Cell Lung Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the PD-1 Non-Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; PD-1 Non-Small Cell Lung Cancer Market Forecast

Some of the key facts of the PD-1 Non-Small Cell Lung Cancer Market Report: 

• The PD-1 Non-Small Cell Lung Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In April 2024, BeiGene announced that the European Commission (EC) has granted approval for TIZVENI (tislelizumab) as a treatment for NSCLC, covering three indications, including both first- and second-line use.

• The PD-(L)1 mNSCLC market size in the US was estimated at approximately USD 6.2 billion in 2023 and is projected to grow further, driven by the introduction of new therapies and expanded indications for existing treatments.

• In 2023, the total number of new non-small cell lung cancer (NSCLC) cases in the 7MM was approximately 524,000, and this number is expected to rise throughout the forecast period.

• In 2023, the incidence of non-small cell lung cancer (NSCLC) cases in the United States was approximately 56% in males and around 44% in females.

• In 2023, the total number of NSCLC cases in the EU4 and the UK was estimated at around 203,220, with Germany recording the highest number of cases among these countries.

• The PD-(L)1 biomarker testing rate in the US is approximately 85%. In Japan, the testing rate is higher compared to the EU4 countries and the UK.

• In 2023, the total number of PD-(L)1 NSCLC cases in the US was approximately 101,300.

• Key PD-1 Non-Small Cell Lung Cancer Companies: Merck, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/ Hoffmann-La Roche, Regeneron/Sanofi, BeiGene, Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, Summit Therapeutics, Seagen, and others

• Key PD-1 Non-Small Cell Lung Cancer Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), TECENTRIQ (atezolizumab), LIBTAYO (cemiplimab-rwlc), TIZVENI (tislelizumab), GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, Ivonescimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, and others

• The PD-1 Non-Small Cell Lung Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage PD-1 Non-Small Cell Lung Cancer pipeline products will significantly revolutionize the PD-1 Non-Small Cell Lung Cancer market dynamics.

PD-1 Non-Small Cell Lung Cancer Overview

PD-1 Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. It is a category of epithelial lung cancer that includes several subtypes with similar treatment approaches and prognoses.

Get a Free sample for the PD-1 Non-Small Cell Lung Cancer Market Report: 

https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-market

PD-1 Non-Small Cell Lung Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

PD-1 Non-Small Cell Lung Cancer Epidemiology Segmentation:

The PD-1 Non-Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of PD-1 Non-Small Cell Lung Cancer

• Prevalent Cases of PD-1 Non-Small Cell Lung Cancer by severity

• Gender-specific Prevalence of PD-1 Non-Small Cell Lung Cancer

• Diagnosed Cases of Episodic and Chronic PD-1 Non-Small Cell Lung Cancer

Download the report to understand which factors are driving PD-1 Non-Small Cell Lung Cancer epidemiology trends @ PD-1 Non-Small Cell Lung Cancer Epidemiology Forecast

PD-1 Non-Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the PD-1 Non-Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers PD-1 Non-Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the PD-1 Non-Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

PD-1 Non-Small Cell Lung Cancer Therapies and Key Companies

• KEYTRUDA (pembrolizumab): Merck

• OPDIVO (nivolumab): Bristol-Myers Squibb/Ono Pharmaceutical

• TECENTRIQ (atezolizumab): Genentech/ Hoffmann-La Roche

• LIBTAYO (cemiplimab-rwlc): Regeneron/Sanofi

• TIZVENI (tislelizumab): BeiGene

• GB226: Genor Biopharma

• BA-1104: Shandong Boan Biotechnology

• PF-06801591: Pfizer

• AZD2936: AstraZeneca

• HX008: Lepu Biopharma

• Dostarlimab: GlaxoSmithKline

• INCMGA00012: Incyte Corporation

• AK-112: Akeso Biopharma

• Zimberelimab: Arcus Biosciences

• Ivonescimab: Summit Therapeutics

• Sasanlimab: Pfizer

• Rilvegostomig: AstraZeneca

• SGN-PDL1V: Seagen

Discover more about therapies set to grab major PD-1 Non-Small Cell Lung Cancer market share @ PD-1 Non-Small Cell Lung Cancer Medication

PD-1 Non-Small Cell Lung Cancer Market Drivers

• Premium-price targeted agents with better clinical profile and expansion of therapies in the first-line expected to drive the growth of NSCLC market

• The development of therapies targeting specific mutations are expected to dominate the upcoming market

PD-1 Non-Small Cell Lung Cancer Market Barriers

• Potential for premium pricing of emerging therapies by showing an edge over current therapies Uptake of potential emerging therapies with better clinical profile, specificity towards mutations occurs in NSCLC and therapies to overcome resistance expected to be fast

Scope of the PD-1 Non-Small Cell Lung Cancer Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key PD-1 Non-Small Cell Lung Cancer Companies: Merck, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/ Hoffmann-La Roche, Regeneron/Sanofi, BeiGene, Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, Summit Therapeutics, Seagen, and others

• Key PD-1 Non-Small Cell Lung Cancer Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), TECENTRIQ (atezolizumab), LIBTAYO (cemiplimab-rwlc), TIZVENI (tislelizumab), GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, Ivonescimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, and others

• PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment: PD-1 Non-Small Cell Lung Cancer current marketed and PD-1 Non-Small Cell Lung Cancer emerging therapies

• PD-1 Non-Small Cell Lung Cancer Market Dynamics: PD-1 Non-Small Cell Lung Cancer market drivers and PD-1 Non-Small Cell Lung Cancer market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• PD-1 Non-Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, PD-1 Non-Small Cell Lung Cancer Market Access and Reimbursement 

To know more about PD-1 Non-Small Cell Lung Cancer companies working in the treatment market, visit @ PD-1 Non-Small Cell Lung Cancer Clinical Trials and Therapeutic Assessment

Table of Contents 

1. PD-1 Non-Small Cell Lung Cancer Market Report Introduction

2. Executive Summary for PD-1 Non-Small Cell Lung Cancer

3. SWOT analysis of PD-1 Non-Small Cell Lung Cancer

4. PD-1 Non-Small Cell Lung Cancer Patient Share (%) Overview at a Glance

5. PD-1 Non-Small Cell Lung Cancer Market Overview at a Glance

6. PD-1 Non-Small Cell Lung Cancer Disease Background and Overview

7. PD-1 Non-Small Cell Lung Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of PD-1 Non-Small Cell Lung Cancer 

9. PD-1 Non-Small Cell Lung Cancer Current Treatment and Medical Practices

10. PD-1 Non-Small Cell Lung Cancer Unmet Needs

11. PD-1 Non-Small Cell Lung Cancer Emerging Therapies

12. PD-1 Non-Small Cell Lung Cancer Market Outlook

13. Country-Wise PD-1 Non-Small Cell Lung Cancer Market Analysis (2020–2034)

14. PD-1 Non-Small Cell Lung Cancer Market Access and Reimbursement of Therapies

15. PD-1 Non-Small Cell Lung Cancer Market Drivers

16. PD-1 Non-Small Cell Lung Cancer Market Barriers

17.  PD-1 Non-Small Cell Lung Cancer Appendix

18. PD-1 Non-Small Cell Lung Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PD-1 Non-Small Cell Lung Cancer Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics

The Presbyopia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.  

DelveInsight’s “Presbyopia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Presbyopia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Presbyopia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Presbyopia Market Insights

Some of the key facts of the Presbyopia Market Report:  

• The Presbyopia market size was valued at USD 17 Billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) 

• In 2023, the United States represented the largest market share for Presbyopia, accounting for approximately 48% of the total market size across the 7MM, compared to other major markets like the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

• In 2023, Germany had the largest Presbyopia market size among European countries, with approximately USD 1,666 million, whereas Spain recorded the smallest market size at around USD 938 million.

• In 2023, the Presbyopia market size in Japan was estimated to be approximately USD 2,642 million, representing 16% of the total market across the 7MM.

• According to DelveInsight’s assessment, the estimated total number of prevalent presbyopia cases across the 7MM in 2023 was approximately 325 million.

• In 2023, the US recorded the highest total diagnosed prevalent cases of presbyopia, with approximately 109 million cases, and this number is expected to increase in the future.

• In 2023, Germany had the highest diagnosed prevalent cases of presbyopia among European countries, with approximately 32 million cases, followed by Italy with around 24 million cases. Spain had the lowest diagnosed prevalent population, with roughly 18 million cases.

• In 2023, Japan reported approximately 50 million diagnosed prevalent cases of presbyopia, representing around 18% of the total cases across the 7MM.

• Key Presbyopia Companies: Ocuphire Pharma, Inc., Novartis, Orasis Pharmaceuticals, Allergan, AbbVie, Orasis Pharmaceuticals, LENZ Therapeutics, Eyenovia, Orasis Pharmaceutical, Ocuphire Pharma, Novartis, Visus Therapeutics, and others 

• Key Presbyopia Therapies: Pilocarpine, UNR844-Cl, CSF-1, AGN-199201, AGN-190584, PresbiDrops (CSF-1), Aceclidine, MicroLine, CSF-1, Nyxol, UNR844, VT-101, Brimochol, and others 

• The Presbyopia epidemiology based on gender analyzed that the prevalence of Presbyopia is higher in females than males 

Presbyopia Overview

According to American Academy of Opthalmology, Presbyopia is a normal part of aging wherein your eyes gradually lose the ability to see things clearly up close. The term “presbyopia” comes from a Greek word which means “old eye.” Most people begin to notice the effect of presbyopia sometime after the age of 40 as the lenses of the eyes naturally lose their elasticity due to the aging process.

Get a Free sample for the Presbyopia Market Report:

https://www.delveinsight.com/report-store/presbyopia-market

Presbyopia Market  

The dynamics of the Presbyopia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.  

“The pipeline for Presbyopia is dynamic, consisting of Orasis Pharmaceuticals (PresbiDrops), Novartis (UNR844), Eyenovia (MicroLine), AbbVie (AGN-241622), Ocuphire Pharma (Nyxol), Visus therapeutics (Brimochol), and others, most of which are expected to launch during the forecast period [2022-2032].” 

Presbyopia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Presbyopia Epidemiology Segmentation:

The Presbyopia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Presbyopia

• Prevalent Cases of Presbyopia by severity

• Gender-specific Prevalence of Presbyopia

• Diagnosed Cases of Episodic and Chronic Presbyopia

Download the report to understand which factors are driving Presbyopia epidemiology trends @ Presbyopia Epidemiological Forecast

Presbyopia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Presbyopia market or expected to get launched during the study period. The analysis covers Presbyopia market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Presbyopia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Presbyopia Therapies and Key Companies

• Pilocarpine: Ocuphire Pharma, Inc.

• UNR844-Cl: Novartis

• CSF-1: Orasis Pharmaceuticals

• AGN-199201: Allergan

• AGN-190584: AbbVie

• PresbiDrops (CSF-1): Orasis Pharmaceuticals

• Aceclidine: LENZ Therapeutics

• MicroLine: Eyenovia

• CSF-1: Orasis Pharmaceutical

• Nyxol: Ocuphire Pharma

• UNR844: Novartis

• VT-101/Brimochol: Visus Therapeutics

Discover more about therapies set to grab major Presbyopia market share @ Presbyopia Medications

Presbyopia Market Drivers

• Rising prevalence of Presbyopia

• An upsurge in launch of products

• Increasing lifestyle changes

• Increasing research in pharmaceutical treatment

• Increase in geriatric population

Presbyopia Market Barriers

• Rising healthcare costs

• Shortage of trained ophthalmologists

• Lack of accessibility of eye care services

• Limitations of Monovision

Scope of the Presbyopia Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Presbyopia Companies: Ocuphire Pharma, Inc., Novartis, Orasis Pharmaceuticals, Allergan, AbbVie, Orasis Pharmaceuticals, LENZ Therapeutics, Eyenovia, Orasis Pharmaceutical, Ocuphire Pharma, Novartis, Visus Therapeutics, and others

• Key Presbyopia Therapies: Pilocarpine, UNR844-Cl, CSF-1, AGN-199201, AGN-190584, PresbiDrops (CSF-1), Aceclidine, MicroLine, CSF-1, Nyxol, UNR844, VT-101, Brimochol, and others

• Presbyopia Therapeutic Assessment: Presbyopia current marketed and Presbyopia emerging therapies

• Presbyopia Market Dynamics: Presbyopia market drivers and Presbyopia market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Presbyopia Unmet Needs, KOL’s views, Analyst’s views, Presbyopia Market Access and Reimbursement 

To know more about Presbyopia treatment, visit @ Presbyopia Treatment Landscape

Table of Contents 

1. Presbyopia Market Report Introduction

2. Executive Summary for Presbyopia

3. SWOT analysis of Presbyopia

4. Presbyopia Patient Share (%) Overview at a Glance

5. Presbyopia Market Overview at a Glance

6. Presbyopia Disease Background and Overview

7. Presbyopia Epidemiology and Patient Population

8. Country-Specific Patient Population of Presbyopia 

9. Presbyopia Current Treatment and Medical Practices

10. Presbyopia Unmet Needs

11. Presbyopia Emerging Therapies

12. Presbyopia Market Outlook

13. Country-Wise Presbyopia Market Analysis (2020–2034)

14. Presbyopia Market Access and Reimbursement of Therapies

15. Presbyopia Market Drivers

16. Presbyopia Market Barriers

17.  Presbyopia Appendix

18. Presbyopia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics

The Polycythemia Vera Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Polycythemia Vera Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Polycythemia Vera Market.

Some of the key takeaways from the Polycythemia Vera Pipeline Report:

• Companies across the globe are diligently working toward developing novel Polycythemia Vera treatment therapies with a considerable amount of success over the years. 

• Polycythemia Vera companies working in the treatment market are Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others, are developing therapies for the Polycythemia Vera treatment 

• Emerging Polycythemia Vera therapies in the different phases of clinical trials are- Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others are expected to have a significant impact on the Polycythemia Vera market in the coming years.   

• In June 2024, AOP Orphan Pharmaceuticals GmbH (AOP Health) continues its successful hematology/oncology clinical research program with two abstracts accepted for presentation at the European Hematology Association (EHA) 2024 hybrid congress in Madrid, Spain. One abstract includes an oral presentation of the latest findings from the PROUD-PV and CONTINUATION-PV trials. The results demonstrate a link between genetic changes (molecular response) and event-free survival (EFS) in polycythemia vera (PV) patients treated with ropeginterferon alfa-2b (BESREMi®) or the best available treatment.

• In February 2024, Disc Medicine has disclosed that the US FDA has awarded Orphan Drug Designation to DISC-3405 for treating patients with PV. Additionally, in September 2023, the FDA granted fast track designation to MWTX-003, also known as DISC-3405, for PV treatment.

• In January 2024, Takeda and Protagonist Therapeutics have established a global licensing and collaboration agreement for rusfertide.

• In September 2023, NICE has endorsed Novartis’s JAKAVI (ruxolitinib) for individuals diagnosed with PV.

Polycythemia Vera Overview

Polycythemia vera (PV) is a rare blood disorder characterized by the overproduction of red blood cells in the bone marrow. This overproduction leads to thickening of the blood, which can slow its flow and increase the risk of clotting.

Get a Free Sample PDF Report to know more about Polycythemia Vera Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight

Emerging Polycythemia Vera Drugs Under Different Phases of Clinical Development Include:

• Rusfertide (PTG-300): Protagonist Therapeutics

• Givinostat (ITF2357): Italfarmaco

• Bomedemstat: Imago BioSciences

• SLN124: Silence Therapeutics

• Sapablursen: Ionis Pharmaceutical

• PPMX-T003: Perseus Proteomics

• PTG-300: Protagonist Therapeutics, Inc.

• SLN124: Silence Therapeutics plc

• Hydroxyurea: Novartis

• Ropeginterferon alfa-2b: PharmaEssentia

• PEG-P-INF alpha-2b (P1101): AOP Orphan Pharmaceuticals AG

• Ruxolitinib: Incyte Corporation

Polycythemia Vera Route of Administration

Polycythemia Vera pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Polycythemia Vera Molecule Type

Polycythemia Vera Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Polycythemia Vera Pipeline Therapeutics Assessment

• Polycythemia Vera Assessment by Product Type

• Polycythemia Vera By Stage and Product Type

• Polycythemia Vera Assessment by Route of Administration

• Polycythemia Vera By Stage and Route of Administration

• Polycythemia Vera Assessment by Molecule Type

• Polycythemia Vera by Stage and Molecule Type

DelveInsight’s Polycythemia Vera Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Polycythemia Vera product details are provided in the report. Download the Polycythemia Vera pipeline report to learn more about the emerging Polycythemia Vera therapies

Some of the key companies in the Polycythemia Vera Therapeutics Market include:

Key companies developing therapies for Polycythemia Vera are – F. Hoffmann-La Roche Ltd, Fujifilm Holdings Corp, Hangzhou Bensheng Pharmaceutical Co Ltd, Protagonist Therapeutics Inc, Ascentage Pharma Group International, Imago BioSciences Inc, and Ionis Pharmaceuticals Inc, and others.

Polycythemia Vera Pipeline Analysis:

The Polycythemia Vera pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Polycythemia Vera with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycythemia Vera Treatment.

• Polycythemia Vera key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Polycythemia Vera Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycythemia Vera market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Polycythemia Vera drugs and therapies

Polycythemia Vera Pipeline Market Strengths

• The approval of BESREMi in the US and its expected approval in Japan, in both the first and second line of treatment, provides the interferon with an immense opportunity to garner a big market size in Polycythemia Vera. 

• Based on increasing sales of JAKAFI/JAKAVI, the drug will be a blockbuster therapy in 2L PV patients

Polycythemia Vera Pipeline Market Opportunities

• An increase in strategic alliances, such as geographical alliances, and granting the designation such as BTD and FTD by the FDA are some of the factors that will drive the market growth.

• Opportunity for drugs with novel and disease-modifying mechanisms and low side effect.

Scope of Polycythemia Vera Pipeline Drug Insight    

• Coverage: Global

• Key Polycythemia Vera Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others

• Key Polycythemia Vera Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others

• Polycythemia Vera Therapeutic Assessment: Polycythemia Vera current marketed and Polycythemia Vera emerging therapies

• Polycythemia Vera Market Dynamics: Polycythemia Vera market drivers and Polycythemia Vera market barriers 

Request for Sample PDF Report for Polycythemia Vera Pipeline Assessment and clinical trials

Table of Contents

1. Polycythemia Vera Report Introduction

2. Polycythemia Vera Executive Summary

3. Polycythemia Vera Overview

4. Polycythemia Vera- Analytical Perspective In-depth Commercial Assessment

5. Polycythemia Vera Pipeline Therapeutics

6. Polycythemia Vera Late Stage Products (Phase II/III)

7. Polycythemia Vera Mid Stage Products (Phase II)

8. Polycythemia Vera Early Stage Products (Phase I)

9. Polycythemia Vera Preclinical Stage Products

10. Polycythemia Vera Therapeutics Assessment

11. Polycythemia Vera Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Polycythemia Vera Key Companies

14. Polycythemia Vera Key Products

15. Polycythemia Vera Unmet Needs

16 . Polycythemia Vera Market Drivers and Barriers

17. Polycythemia Vera Future Perspectives and Conclusion

18. Polycythemia Vera Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Polycythemia Vera Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials | Roche, Fujifilm Holdings Corp, Hangzhou Bensheng Pharma, Protagonist Therapeutics, Ascentage